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MicroRNAs (miRNAs) are endogenous short (20–22
nucleotides) non-coding RNA molecules that mediate gene
expression. This is an important regulatory mechanism
to modulate fundamental cellular processes such as
differentiation, proliferation, death, metabolism, and
pathophysiology of many diseases. The miRNA expression
profile of the kidney differs greatly from that of other organs,
as well as between the different regions in the kidney. In
kidneys, miRNAs are indispensable for development and
homeostasis. In this review, we explore the involvement of
miRNAs in the regulation of blood pressure, hormone, water,
and ion balance pertaining to kidney homeostasis. We also
highlight their importance in renal pathophysiology, such as
in polycystic disease, diabetic nephropathy, nephrogenic
diabetes insipidus, hypertension, renal cancer, and kidney
fibrosis (epithelial–mesenchymal transition). In addition, we
highlight the need for further investigations on miRNA-based
studies in the development of diagnostic, prognostic, and
therapeutic tools for renal diseases.
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Kidneys are responsible for the regulation of fluid, water,
electrolytes, and arterial blood pressure, and also for the
elimination of toxins such as the waste products of metabolic
activity.1 They perform several essential tasks, including the
maintenance of blood pH/acid–base balance, calcium meta-
bolism, and the release of important hormones such as
erythropoietin.
MICRORNAs (miRNAs)—BIOGENESIS AND FUNCTION
miRNAs are endogenous, short (20–22 nucleotides in length)
non-coding RNAs that control the expression of many
genes.2 Since their discovery, miRNAs have been associated
with several physiological activities, such as tissue develop-
ment, lipid metabolism, cell differentiation, apoptosis, and
stem cell division.3–5 In humans, approximately 70% of
known miRNAs reside in non-protein-coding regions of the
genome, while the remaining 30% are transcribed from the
intergenic regions.6
miRNA biogenesis begins in the nucleus, where miRNA
genes are transcribed by RNA polymerase II, and in some
cases by RNA polymerase III, to produce long primary
miRNAs. These primary miRNAs consist of one or more
stem-loop structures, each with a 7-methylguanosine cap and
a poly A tail.7,8 A microprocessor complex in the nucleus
comprising the RNase III Drosha and pasha (double-
stranded RNA-binding protein) trims the primary miRNAs
into precursor miRNAs (pre-miRNAs), which are basically
hairpin structures about 70 nucleotides long.9 Pre-miRNAs
are transported into the cytosol by exportin 5 and further
processed by another RNase, Dicer, into mature, 18–22-
nucleotide-long miRNAs (Figure 1; ref. 4). One strand of the
mature miRNA enters the RNA-induced silencing complex
and binds to the 30 untranslated region of the target
messenger RNA (mRNA).10,11 The binding of miRNAs to
mRNA targets reduces the expression level of the protein.
A perfect match between miRNA and its target results in
cleavage of the latter by the RNA-induced silencing complex,
while imperfect binding leads to translational repression. The
miRNA-repressed mRNA is engulfed into P-bodies for
storage or decay (Figure 1; ref. 12). Recently, several studies
have shown that miRNAs also have a role in gene activation.
In such situations, miRNAs are trafficked back into the
nucleus and can therefore modulate gene expression (Figure 1;
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refs 13–15). For more information on biogenesis and function
of miRNAs, several reviews16–23 can be consulted.
miRNAs AS REGULATORS OF KIDNEY HOMEOSTASIS
Although the biochemistry and physiology of kidney
function has been thoroughly understood for a very long
period of time, it is only in recent years that the involvement
of miRNAs in kidney regulation has become apparent. It is
now clear that miRNAs form a vital part of the regu-
latory cascade in renal development, maintenance of renal
function, and progression of kidney diseases.24,25 miRNAs
such as miR-192, miR-194, miR-204, miR-215, and miR-216
are expressed abundantly in the kidneys.26 Bioinformatic
analysis by Tian et al.27 showed that miR-192 expression was
20-fold higher in the renal cortex than in the medulla. The
group also reported that miR-192 was involved in regulation
of the molecular machinery of sodium transport in kidney
epithelial cells.
Regulation of body water by the kidneys is known to
take place via several integral membrane proteins or channels
known as aquaporins (AQPs).28–30 About seven different
AQPs, AQP1, 2, 3, 4, 6, 7, and 11, are expressed in the kidney
(Figure 2). AQP1, which is strongly expressed in the plasma
membrane of the proximal tubules and descending thin limb,
has been reported as the most important water channel for
transepithelial water permeability in these regions.31 Indivi-
duals with AQP1 deficiency have impaired urine-concentrat-
ing ability.32 AQP2 is a vasopressin-sensitive water channel
that regulates water homeostasis in the distal tubules and the
collecting ducts. Arginine vasopressin mediates the transloca-
tion of intracellular vesicle-encapsulated AQP2 to the apical
plasma membrane, thus facilitating water reabsorption from
urine into the principal cells in the kidney.33–35 Under condi-
tions such as hypovolemia or hypernatremia, the arginine
vasopressin released by the pituitary gland binds to
vasopressin receptors in the epithelial cells of the collecting
duct.36 Arginine vasopressin binding specifically activates the
vasopressin type 2 receptor, which in turn triggers a signaling
cascade that results in the stable translocation of the
intracellular vesicle-bound AQP2 to the apical membrane.36
Of the 40 mutations that have been found in the AQP2 gene,
8 have been associated with dominant nephrogenic diabetes
insipidus and the remaining ones with autosomal-recessive
nephrogenic diabetes insipidus.37,38 Nephrogenic diabetes
insipidus patients lose their ability to concentrate urine
despite having normal or raised levels of vasopressin.37,39,40
AQP3 is also postulated to have a role in urine concentration,
as a nephrogenic diabetes insipidus-like phenotype occurs
in AQP3 knockout mice.41 AQP3 has been found to be
co-localized with AQP4 in the basolateral membranes of
collecting ducts.42 AQP3 along with AQP4 forms a potential
exit pathway for water that enters the cell via AQP2. AQP3
expression has been found to be increased by thirst and in the
presence of vasopressin or aldosterone.43 In addition,
deletion of AQP3 has been found to diminish AQP2
expression, resulting in reduced permeability of the baso-
lateral membrane of the cortical collecting duct, which
potentially leads to polyuria.44 AQP4 is regulated by
vasopressin45 and also has a role in urine concentration.
Nevertheless, its deletion caused only a mild impairment
in the urine-concentrating ability as compared with the
other AQPs.41,46 AQP6 is present in intracellular vesicles of
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Figure 1 |MicroRNA (miRNA)—biogenesis and function. The biosynthesis of miRNAs, as well as their activity in translational repression
(RNA interference (RNAi)) and transcriptional modulation (RNAa or RNAi), is represented diagrammatically. Pre-miRNA, precursor miRNA;
RISC, RNA-induced silencing complex; RNAa, RNA activation.
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acid-secreting a-intercalated cells of the collecting ducts and
assists in urinary acid secretion.47,48 AQP7, an aquaglycero-
porin localized in the brush border of proximal straight
tubules (S3 segment),49 is involved in the transport of
glycerol as well as water.50 Lastly, knocking out AQP11 that is
localized in the intracellular vesicles of the proximal tubules
led to the formation of cysts and resulted in renal failure,
which is similar to polycystic kidney disease (PKD).51–53
miRNA prediction programs suggest large numbers of
miRNAs are capable of regulating the expression of AQPs
(Figure 2; ref. 54). Yet, only one miRNA (miR-320a) has been
experimentally validated. This study showed a direct inter-
action of miR-320a with its mRNA targets, AQP1 and 4.55
More studies of this type are needed to identify miRNAs that
regulate the expression of the other AQPs.
Besides regulation of water re-absorption, the kidney has a
major role in the maintenance of electrolyte homeostasis in
the body.56 Electrolyte movements in cells are controlled by
various ion channels and transporters that are present in the
various nephron segments (Figure 2; refs 57–65).
Osmotic responses in embryonic zebrafish has been found
to be regulated by the miR-8/miR-141/miR-200/miR-236
family of miRNAs. miR-200b was specifically shown to target
the Na/H exchange regulatory factor-1, a regulator of apical
trafficking of transmembrane ion transporter.66 Osmotic
response element binding protein (OREBP) is a transcription
factor that regulates cellular osmoregulation in the kidney
in mammals. It has been shown that hypertonicity could
increase the stability of OREBP mRNA and induced
expression of the OREBP protein. Extrapolating the findings
in zebrafish to mammalian kidney cells, Huang et al.67
identified that the OREBP expression in mouse renal cells
and kidneys could be regulated by miRNAs. Overexpression
of OREBP protein was observed with the inhibition of
miR-200 and miR-717. The authors found that exposure of
kidney cells to hypertonic (high NaCl; 500mOsmol/kg
H2O) medium significantly downregulated the expression
of miR-200b, miR-143, and miR-717. miR-200 and miR-717
were found to be tightly connected to tonicity (sensitive and
responsive), for they could repress the mRNA and protein
expression of OREBP. Interestingly, the expression of miR-
200b and miR-717 was found to be greatly upregulated in
aldose reductase–deficient (AR/) mice (a mouse model for
the urine-concentrating mechanism) and furosemide-treated
mice.67
Another central role for kidneys is the regulation of
blood pressure through the renin and renin–angiotensin
system (Figure 2; refs 56, 68–70). Renin, angiotensinogen,
and angiotensin-converting enzyme are the main compo-
nents of the renin–angiotensin system, which are localized in
a site-specific manner within the kidney.71–75 Renin is a glyco-
protein enzyme and its biosynthesis takes place as prorenin in
the juxtaglomerular cells of the renal afferent arterioles.76–78
Prorenin is converted to active renin by a trypsin-like
activating enzyme.79 Active renin cleaves angiotensinogen to
an inactive angiotensin I. Angiotensin-converting enzyme
hydrolyzes the inactive angiotensin I into biologically active
angiotensin II, a potent vasoconstrictor.80,81 The renin–angio-
tensin system also increases aldosterone secretion from
the adrenal zona glomerulosa, which then acts on the
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kidney.82 Aldosterone increases the reabsorption of sodium
and water and the secretion of potassium in collecting ducts
and distal tubules. This could cause a rise in blood pressure
due to an increase in blood volume.82
A recent study by Sequeira-Lopez et al.,78 where a condi-
tional deletion of Dicer was carried out, showed that
expression of renin in the juxtaglomerular cells was
controlled by miRNAs. Dicer deletion had been shown to
cause hypotension due to downregulation of the renin genes
(Ren 1 and Ren 2; Figure 2; ref. 78).
miRNAs IN KIDNEY DEVELOPMENT
miRNAs are also important for renal development24,83
starting from nephrogenesis (renal embryology) to renal
senescence. Nephrogenesis comprises three main stages:
pronephros (cervical kidney), which develops at the begin-
ning of the fourth week of gestation, followed by meso-
nephros (thoracic kidney), which begins to progress as soon
as the pronephros degenerates around the fifth week, and
lastly metanephros, also known as the definitive abdominal
kidney that forms the final adult kidneys. The metanephros
continues to grow in size until puberty.84 As it approaches the
fifth decade of life, renal growth declines progressively with
advanced age, a stage called the renal senescence. miRNA
profiling of kidneys (in various stages of growth) will be the
first important step in identifying renal miRNAs involved
in renal development. Few studies have profiled miRNA
expression in human organs, including the kidneys. Putting
all these studies together, we now know that miR-146a,
miR-886, miR-192, miR-194, miR-204, miR-215, and
miR-216 are the few miRNAs that were found to be renal-
specific, while others such as let-7a-g, miR-196a/b, miR-10a/b,
miR-130, miR-143, miR-21, miR-200a, miR-30a-e, and miR-
872 have also been reported to be expressed in the kidneys.85–87
The involvement of miRNAs in renal development begins as
early as its regulation of the nephron progenitors. A very recent
study by Nagalakshmi et al.88 reported that ablation of
Dicer function within the nephron progenitors and the ureteric
bud-derived collecting duct system resulted in increased
apoptosis and premature termination of nephrogenesis accom-
panied by development of renal cysts. This implies that
Dicer function is critical for maintaining the viability of the
nephron progenitors and consequently the development of the
nephrons. An independent study by Ho et al.89 supported these
findings as well. Ho et al.89 reported that the loss of miRNAs in
nephron progenitors led to a premature depletion of this
population as renal growth progressed. The authors performed
miRNA profiling during nephrogenesis and identified a pool of
miRNAs, particularly miR-10a, miR-106b, and miR-17–5p,
which were predicted to regulate Bim, a pro-apoptotic protein
that increased during the depletion of the nephron progenitors.
Subsequent loss of these miRNAs increased apoptosis and
resulted in depletion of the nephron progenitors.89
Apart from early renal development, miRNAs have also
been found to participate in renal senescence. Although the
molecular basis of this process is not completely understood,
a study by Bai et al.90 discussed the involvement of miRNAs
in the aging of kidneys. The authors profiled miRNA
expression in the young (3-month) and old (24-month) rat
kidneys and identified the biological pathways and genes that
are targeted by the differentially expressed miRNAs. Upon
aging of the kidneys, 18 miRNAs that were predicted to
target genes regulating energy metabolism, cell proliferation,
antioxidative defense, and extracellular matrix degradation
processes were found to be upregulated. On the other hand, a
cluster of seven downregulated miRNAs were thought to be
involved in the immune inflammatory response and cell-
cycle arrest processes. Among these miRNAs, the authors
focused on two highly upregulated miRNAs, miR-335 and
miR-34a, which were accompanied by a marked decrease
in the expression of SOD2 and Txnrd2 genes. Overexpression
of miR-335 and miR-34a was found to lead to premature
senescence of the young mesangial cells via SOD2 and Txnrd2
suppression, while their ablation showed a decrease in
senescence of the old mesangial cells. Combining these
studies together, Bai et al.90 showed that miRNAs form
important regulators of renal development. This hypothesis is
held true in studies where disrupted miRNA biogenesis
resulted in rapid progression of end-stage renal disease.
Podocyte abnormalities arising within the first few
weeks after birth can cause effacement, vacuolization, and
hypertrophy.24 In Dicer knockout mice, podocyte-specific
loss of miRNAs caused proteinuria by the second week
after birth. This was followed by rapid progression of
glomerular and tubular injury by the third week and finally
resulted in death by 4 weeks due to renal failure in the
fourth week. Three miRNAs (miR-23b, miR-24, and miR-
26a) have been identified in the glomeruli as contributors
of renal failure.91 Inhibition of miRNA function through
inactivation of Dicer resulted in multiple abnormalities
such as irregular and split areas of the glomerular basement
membrane, podocyte apoptosis and depletion, capillary
dilation, and glomerulosclerosis.92 Similarly, podocyte-
specific deletion of Drosha has been found to result in
proteinuric renal disease and collapsing glomerulopathy due
to loss of miRNAs.93
miRNAs IN RENAL DISEASE
Polycystic kidney disease
PKD is a disorder in which clusters of cysts develop to
contain water-like fluid in the renal epithelial cells. The PKD1
and PKD2 genes encode for polycystin 1 and 2, respectively,
while the PKHD1 gene encodes for fibrocystin/polyductin.
Cyst formation in the kidneys is due to mutations or
dysregulated expression of the PKD1, PKD2, or PKHD1.
Abnormal expression of these genes leads to disrupted cell
division, proliferation,94 and deregulated cell–matrix and/or
cell–cell interactions.95,96 Genetic inheritance of the PKD/
PKDH1 genes results in either an autosomal dominant
(ADPKD) or an autosomal recessive (ARPKD) disease. The
more prevalent ADPKD is linked to mutations in either
PKD1 or PKD2.97 ARPKD, which has a high mortality rate, is
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caused by mutations of the polycystic kidney and hepatic
disease 1 (PKHD1) gene.98,99
One of the 12 types of mutations listed in the ADPKD
mutation database (http://pkdb.mayo.edu/) is the silent
mutation at the 30 untranslated region of the genes.100 About
70–80% of adults with ADPKD are diagnosed with
hypertension before the loss of kidney function.101 Kidney
volume is significantly increased in hypertensive patients
with ADPKD compared with normotensive states.102,103
Approximately 50% of ADPKD patients have left ventricular
hypertrophy by their fourth decade of age.104
The role of miRNA in PKD pathogenesis was demon-
strated by Pandey et al.,105 who observed differential expres-
sion of miRNAs in the kidneys of PKD rat model. The
dysregulated miRNAs were mapped to signal transduction
pathways such as TGF-b, mammalian target of rapamycin
signaling pathway, mitogen-activated protein kinase, calcium
signaling pathway, Wnt, and Janus kinase/signal transducer
and activator of transcription signaling pathways, which have
been previously described in PKD pathogenesis.105
Subsequently, Sun et al.106 showed that miR-17 directly
targets PKD2 and could have a role in cytogenesis. The
interference of PKD2 expression by miR-17 family was further
demonstrated by Tran et al.107 The authors showed that Bicc1
(RNA-binding protein bicaudal 1), a post-transcriptional
regulator of PKD2, interferes with the binding of miR-17 family
at the 30 untranslated region of PKD2 mRNA.106,107 This results
in enhancing the translation of PKD2 mRNA in non-disease
models, while the loss of Bicc1 exhibits a PKD-like phenotype.108
Based on an extensive mRNA array, Pandey et al.109 predicted
and verified several miRNAs (miRs-10a, miR-30a-5p, miR-96,
miR-126–5p, miR-182, miR-200a, miR-204, miR-429, and
miR-488) to be negatively regulated by the differentially
regulated mRNA in a Pkd1/ mouse model.109 They pro-
posed a common mRNA expression pattern between the mouse
model and humans with ADPKD. The authors also suggested
that the differentially regulated mRNA:miRNA targets may have
an important role in cellular signaling events leading to PKD.
However, in the case of ARPKD, Lee et al.110 demonstrated
that miR-15a could repress the cell division cycle 25A
(Cdc25A) protein expression, resulting in inhibition of cell
proliferation and cell cycle. Cdc25 has an essential role in cell-
cycle progression, and the overexpression of Cdc25A in some
cancers is frequently correlated with tumor grades and
aggressiveness, as well as with poor prognosis.111 The
expression of miR-15a is reduced both in an animal model
of ARPKD (PCK rat model) and in a cholangiocyte cell line
(PCK-CCL) as well as in the cholangiocytes lining liver
cysts in patients with ADPKD and ARPKD.110 Reduction in
miR-15a promotes the increased expression of Cdc25A, thus
promoting cyst growth in the disease conditions.
Diabetic nephropathy
Diabetic nephropathy is associated with high morbidity and
mortality.112 It occurs in 50% of the patients with type 2
diabetes mellitus113–115 and is the single most significant cause
of end-stage renal disease. Uncontrolled high blood sugar along
with high blood pressure can lead to kidney damage, but the
exact cause of diabetic nephropathy is unknown. In some cases
hereditary factors or family history seems to have a vital role, as
shown by epidemiological studies. Only a minority of patients
with diabetes have been found to develop nephropathy
irrespective of glycemic control.116
High blood sugar causes damage to the kidneys by causing
thickening of the glomerular basement membrane and
mesangial expansion. It also results in arteriolar, tubular,
and interstitial lesions.117 In both type 1 and type 2 diabetes
with overt nephropathy, the decline of renal function
correlates strongly with hypertension, higher systolic blood
pressure, and serum triglyceride levels.118 In microalbumin-
uric patients, hypertension correlates with the degree of
albuminuria.119 Antihypertensive therapy is useful in both
these situations. In normoalbuminuric type 1 diabetes, slight
increases in blood pressure have been correlated with the
subsequent development of microalbuminuria.120 Involve-
ment of miRNAs in the regulation of diabetic nephropathy
has been neatly reviewed in depth by Lorenzen et al.121
The miR-192 and miR-200b/c pair is associated with
diabetic glomeruli and regulates kidney function along with
Smad-interacting protein 1, transforming growth factor beta 1
(TGF-b1), delta 1–crystallin enhancer binding protein, and
collagen type 1 alpha 2 Col1a2.122–124 TGF-b1 upregulates
miR-192/miR-200 and this causes downregulation of Smad-
interacting protein 1 and dEF1 (Figure 3). The combined
reduction in expression of Smad-interacting protein 1 and delta
13–crystallin enhancer binding protein enhances Col1a2
expression,122 which leads to accumulation of extracellular
matrix proteins. These proteins are responsible for glomer-
ular and tubular hypertrophic growth, which is charac-
teristic of diabetic nephropathy (Figure 3). In diabetic mice,
as well as in renal biopsy samples from diabetic patients, miR-
192 has been found to be poorly expressed. This decrease in
expression of miR-192 is directly correlated with tubulointer-
stitial fibrosis and low glomerular filtration rate in diabetic
individuals.125 TGF-b1 suppresses miR-192 expression in
cultured proximal tubular cells and hence TGF-b1 may regulate
miR-192 differently in mesangial vs. proximal tubular cells.125
Kato et al.126 also observed that miR-216a and miR-217
expression in mesangial cells in diabetic nephropathy can be
regulated by TGF-b1. Akt, a key mediator of diabetic
nephropathy, has been found to be activated when these
miRNAs target the phosphatase and tensin homolog. Wang
et al.127 associated miR-377 with diabetic nephropathy and its
enhanced expression has been reported to be accompanied by
increase in fibronectin levels by repressing p21-activated
kinase and manganese superoxide dismutase. The other
miRNAs that have been implicated in diabetic nephropathy
include miR-21,128 miR-29a,129 miR-29c,130 and miR-93.131
Kidney cancer
Renal cell carcinoma (RCC) typically develops in the
proximal tubules.132–134 The subtypes of RCC include clear
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cell RCC (ccRCC), papillary RCC, chromophobe RCC, and
collecting duct carcinoma.135 The ccRCC has the highest
mortality rate (at over 40%)136 and accounts for nearly
80–85% of kidney tumors in humans.137 Transitional cell
carcinoma of the renal pelvis accounts for the remaining
15–20% of the cases, while conditions such as angiomyoli-
poma or nephroblastoma (Wilms’ tumor) are extremely
rare.137 miRNA dysregulation has been widely studied and
demonstrated in cancer pathogenesis, including RCC. Most
studies to date have compared miRNA profiles of normal
kidney to RCC133,134,138–140 and within RCC subtypes.135,141
miRNA profiling in kidney cancers revealed that miR-28,
miR-185, miR-7–2, and let-7f-2 were significantly upregu-
lated in cancer compared with normal kidney.132 Similarly,
Juan et al.139 also found 9 upregulated miRNAs (miR-34b,
miR-224, miR-142-3p, miR-185, miR-34a, miR-21, miR-155,
miR-210, and miR-592) that could distinguish RCC from
normal kidney. Increased expression of miR-210 in RCC has
been shown to be related to the hypoxic stimuli and angiogenic
pathways and can serve as a prognostic marker for patient
survival.142–145 Furthermore, White et al.145 demonstrated
that dysregulated miRNA expression in RCC could be cor-
related with its chromosomal aberration. The authors also
proposed a correlation between miR-155 and tumor size.
miR-34a/b/c that target the tumor suppressor gene, p53,
has been found to epigenetically silence the CpG methylation
of the p53 promoter region in a number of human cancers,
including kidney and bladder cancers (Figure 3; refs 146,147).
miR-141 and miR-200c have been found to be consistently
downregulated in ccRCC. When miR-141 and miR-200c were
downregulated in ccRCC, ZFHX1B, a transcriptional repres-
sor for CDH1/E-cadherin, was upregulated.148 miR-16 was
also upregulated in RCC. This miRNA could potentially
regulate apoptosis and cell proliferation.138 It is located at
chromosome 13q14 and may interfere with either oncogenic
or tumor suppressor pathways.138
Enhanced expression of the transcription factor E2F3 in
metastatic tissue has been associated with high levels of the
Kidney cancer
miR-34a/b/c
p53
Apoptosis and cell
cycle arrest
miR-141, -200c
ZFHX1B
CDH1/E-cadherin
Cell detachment
(metastasis)
Oncomir-1
family
Cell proliferation Wilms’ tumor
miR-483-3p
(antiapoptotic)
miR-200a, -200b, -429
Cell proliferation and cyst formation
miR-17PKD2
Polycystic kidney disease
IgA nephropathy
miR-130b, -608, -124a, -15b_MM1 miR-150, -92b_MM2
miR-200 family, -205, -192
Lupus nephritis
Hypertension-related renal diseases
Hypertensive nephrosclerosis
miR-29b
Collagen genes,
MMP2, Itgb1
Medullary injury
Diabetic nephropathy
miR-377
miR-93
mnSOD
VEGF pathway
Fibronectin
EMT
Apoptosis and
ECM
PAK1
miR-29c
Spry 1
Fibrotic kidney disease
miR-192,-215 miR-200b miR-200a
ZEB 1/2 ZEB 1/2 TGFB2,
matrix protein,
Smad3 action
EMT EMT
Collagen type I/III,
fibronectin
Tubulointerstitial
fibrosis
E-cadherin
Diabetes
TGF-β
miR-29a
Col14a1 and
Co14a2
miR-192
δEF1/SIP1
E-box ---
Collagen
Col1a2
E-box ---     Rp23
miR-216, -217, -21
PTEN
AKT and PI3K
Hypertrophy
Renal
diseases
1
1
1
2 3
1
1
2 3
2 3
2
2
3 4
Figure 3 |MicroRNAs (miR) in renal diseases. Possible miRNA-regulatory networks involved in renal pathophysiology as described in
text are shown. Col1, collagen type 1; ECM, extracellular matrix; dEFI, delta 1–crystallin enhancer binding protein; EMT, epithelial–mesenchymal
transition; Ig, immunoglobulin; Itgb1, integrin beta 1; miRNA, microRNA; MMP2, matrix metalloproteinase 2; mnSOD, manganese
superoxide dismutase; PI3K, phosphoinositide kinase-3; PKD, polycyctic kidney disease; PTEN, phosphatase and tensin homolog;
SIP1, smad-interacting protein; TGF-b, transforming growth factor beta; VEGF, vascular endothelial growth factor; ZEB, zinc finger
E-box-binding homeobox.
622 Kidney International (2012) 81, 617–627
rev iew K Chandrasekaran et al.: MicroRNAs in renal function
oncogenic clusters of miRNAs located on chromosome 13.149
Kort et al.150 studied the combined expression profile of both
mRNA and miRNA to identify expression patterns that are
unique to Wilms’ tumor. They observed the expression of an
oncomir-1 family of miRNAs (miR-17-5p, miR-18a, miR-
19b, miR-20a, and miR-92) to be higher in Wilms’ tumor
than in any other kidney tumor subtypes.150 In addition to
the oncomiR-1 family, decreased expression of miR-562,
which is critical for renal development, and increased
expression of miR-483-3p, which has potential oncogenic
activity (or antiapoptotic oncogene), have been detected in
Wilms’ tumor.151,152
Chow et al.153 validated the miR-17-92 cluster over-
expression in ccRCC by quantitative polymerase chain
reaction and also observed increased cell proliferation in a
renal adenocarcinoma cell line following transfection with
miR-17-5p and miR-20a. A compilation of the available list
of dysregulated miRNAs in RCC has revealed proliferation,
angiogenesis/hypoxia, apoptosis, tumorigenesis, invasion,
and metastasis pathways to be impaired in kidney cancer
pathogenesis.144
Furthermore, two recent studies have demonstrated that
differential miRNA expression could form a base for RCC
subtype identification.135,139 The specific miRNA patterns
could also be correlated with prognosis.139 By using the 91
statistically significant and differentially regulated miRNAs
among the RCC subtypes, Youseff et al.135 identified the
subtype of RCC quite accurately based on a ‘decision tree’.
Thus, miRNA signature patterns could also aid in diagnosis
of the disease.135,154,155
Hypertension-related kidney disease
Chronic hypertension can result in damage to the renal
system, leading to hypertensive kidney disease or nephro-
sclerosis.156,157 The specific link between essential hyper-
tension and nephrosclerosis is controversial, as these
abnormalities have also been seen in aging diabetic nephrop-
athy and in advanced stages of various nephropathies.158–160
Wang et al.161 found the levels of miR-200 family, miR-
205, and miR-192 to be higher in hypertensive nephro-
sclerosis (Figure 3). The severity of sclerosis in the kidneys is
increased when these miRNAs are upregulated. Furthermore,
the intrarenal expression levels of miR-200a, miR-200b,
miR-141, miR-429, miR-205, and miR-192 were shown to be
increased in renal biopsy specimens of patients with
hypertensive nephrosclerosis. Among the miRNAs that were
found to be differentially expressed, increased expression of
miR-29b was observed in the renal medulla of consomic SS-
13 (BN) rats compared with Dahl salt-sensitive rats. miR-29b
was found to regulate 20 collagen genes, matrix metallopro-
teinase 2 (Mmp2), integrin beta1 (Itgb1) and several other
genes. Knockdown of miR-29b was associated with upregu-
lated expression of several collagen genes.162 miR-29b has
also been found to be upregulated in renal medullary tissues,
with a negative regulatory effect on collagen and extracellular
matrix accumulation in hypertensive renal injury.162
Lower nephron numbers have been correlated with
increased blood pressure and kidney diseases such as glomer-
ular hypertrophy and intraglomerular hypertension.163–168
Nephron number has been shown to be associated with birth
weight, race, age, and gender.166,169–171 From autopsy samples
of white patients from Germany, Keller et al.172 observed
reduced glomerular numbers in the kidneys of subjects with
hypertension or left ventricular hypertrophy compared with
normal individuals. Higher glomerular volume was found
in autopsies of kidneys with hypertension-related kidney
disease.166,168,171,172 Increased hypertension was also asso-
ciated with age, glomerular enlargement, intimal thickening,
and higher rates of glomerulosclerosis. Nevertheless, Hoy
et al.167 considered that low glomerular number is an
important determinant of hypertension and renal disease.
miR-155 controls blood pressure by downregulating the
expression of the angiotensin II type 1 receptor as elevated
levels of angiotensin II type 1 receptor are known to cause
hypertension.173 Moreover, increased levels of miR-155 and
decreased levels of angiotensin II type 1 receptor were found
in fibroblasts of trisomy individuals who exhibited low blood
pressure.174
Fibrotic kidney disease
Renal fibrosis is a common feature of many chronic kidney
diseases. Epithelial–mesenchymal transition, a process in
which fully differentiated tubular epithelial cells are pur-
ported to undergo transition to a mesenchymal phenotype
giving rise to fibroblasts and myofibroblasts in diseased
kidneys, has become one of the most investigated and
controversial topics in renal fibrosis.175–180 Loss of expression
of the miR-200 family (miR-200a, miR-200b, miR-200c,
miR-141, and miR-429) may have a critical role in the
repression of E-cadherin by zinc finger E-box-binding
homeobox (ZEB)1 and ZEB2 during EMT. It appears to
enhance cell migration and invasion during metastasis.181–183
miR-200b precursor at 0.5 nmol/l has been found to be
capable of ameliorating renal tubulointerstitial fibrosis
by inhibiting the synthesis of collagen types I and III and
fibronectin.184 miR-200a and miR-141 were found to be
necessary for the development and progression of
TGF-b1–dependent EMT and fibrosis in vitro and in vivo.
miR-200a has also been reported to prevent renal fibrogenesis
by repressing TGF-b2 expression and causing downregulated
expression of matrix proteins and Smad-3 activity (Figure 3;
ref. 185). Ectopic expression of miR-192/miR-215 repressed
translation of ZEB2 mRNA in the presence and absence of
TGF-b, but increased E-cadherin levels.186 Kriegel et al.187
found that E-cadherin expression, which is involved in the
phenotypic change of the cells during renal fibrosis in
diabetic kidney, was enhanced when miR-382 was inhibited
or superoxide dismutase 2 was overexpressed. Recently, Qin
et al.188 showed that miR-29 could inhibit the TGF-b/Smad3-
mediated renal fibrosis only in in-vitro studies. In contrast,
upregulation of miR-192 (highly expressed in kidney)
mediates activation of TGF-b/Smad signaling in the fibrotic
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kidney in both in-vivo and in-vitro conditions.189 The
authors showed that TGF-b1 regulates miR-192 expression
positively by Smad3, thereby demonstrating a role for
miR-192 in renal fibrosis.
Other chronic kidney diseases
Differential expression of miRNAs was observed in patients
with lupus nephritis.190 Among the differentially expressed
miRNAs, miR-371-5p, miR-1224-3p, and miR-423-5p were
found to be unique among Americans of African-origin and
Americans of European-origin groups.191
In immunoglobulin A nephropathy, also known as
Berger’s disease, Wang et al.192 found the level of intrarenal
miR-200c to be decreased and miR-141, miR-205, and
miR-192 to be increased. This was not observed in non-
inflammatory glomerulosclerosis patients. miR-200a, miR-
200b, and miR-429 have been found to be downregulated in
IgA nephropathy patients and the levels correlated with the
rate of progression and severity of disease (Figure 3; ref. 193).
CONCLUSION
miRNAs are being increasingly found to have important
regulatory roles in the development, physiology, and main-
tenance of adult-kidney microstructure. Though expression
profiles of miRNAs in various renal diseases have already
been examined, further studies are needed for a thorough
understanding of the roles of miRNAs in renal pathophysiol-
ogy. miRNAs form valuable tools for diagnosis and prognosis
of several kidney diseases. This review provides an overview
on the crucial roles that miRNAs have in renal function and
diseases. The involvement of miRNAs in various kidney
diseases/pathogenesis is depicted in Figure 3.
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